Drugs / ACAM3000 MVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00133575 | Oct 2005 → Apr 2008 | smallpox | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACAM 3000 MVA | “ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination” NCT00133575 ↗1“MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart” NCT00133575 ↗ |
| Known as | Modified Vaccinia Ankara | “ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination” NCT00133575 ↗ |
| Modality | Vaccine | “A particularly promising vaccine approach to the development of an effective, yet less reactogenic vaccine to smallpox is the use of Modified Vaccinia Ankara (MVA) as a vaccine.” NCT00133575 ↗ |
| Route | Intramuscular | “intramuscularly (IM)” NCT00133575 ↗ |